Schafer Joshua 4

What Happened

• Joshua Schafer, Chief Commercial Officer of Zevra Therapeutics (ZVRA), sold 10,500 shares on 2026-02-03. The weighted-average sale price was $9.19 per share, for a total value of roughly $96,500. This was a sale (S) reported as open-market/private sale activity.

Key Details

• Transaction date: 2026-02-03.
• Price: weighted average $9.19; individual trade prices ranged from $8.92 to $9.55 (multiple trades; reporting person can provide detailed breakdown on request).
• Shares sold: 10,500; approximate proceeds: $96,500.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: transaction executed under a 10b5-1 trading plan adopted 3/27/2025 (F1). Reporting person offered to supply full trade-by-trade details if requested (F2).
• Timeliness: filing shows reporting date 2026-02-04 for a 2026-02-03 transaction; no late-filing indication in the provided data.

Context

• This was a sale, which is often routine and may be executed under pre-arranged 10b5-1 plans; it is not, by itself, evidence of company performance. No options were exercised and no awards or gifts were involved.